Early Detection and Minimal Residual Disease: Liquid Biopsy Market...

eine Datei hinzugefügt Health

2026-02-19 08:34:09 -

Early Detection and Minimal Residual Disease: Liquid Biopsy Market Growth Opportunities in Oncology and Non-Invasive Diagnostics

7 multimodal genomic assays expanding cancer detection in 2026 As 2026 unfolds, the shift toward multi-cancer early detection (MCED) via non-invasive testing is fundamentally altering the global oncology landscape. Regulatory agencies in the European Union and North America have recently streamlined the approval of multimodal genomic assays that analyze circulating tumor DNA (ctDNA) and...

0 Kommentare 0 Anteile 605 Ansichten